> Detailanzeige
Cervia, Carlo
[Verfasser:in];
Nilsson, Jakob
[Verfasser:in];
Zurbuchen, Yves
[Verfasser:in];
Valaperti, Alan
[Verfasser:in];
Schreiner, Jens
[Verfasser:in];
Wolfensberger, Aline
[Verfasser:in];
Raeber, Miro E.
[Verfasser:in];
Adamo, Sarah
[Verfasser:in];
Weigang, Sebastian
[Verfasser:in];
Emmenegger, Marc
[Verfasser:in];
Hasler, Sara
[Verfasser:in];
Bosshard, Philipp Peter
[Verfasser:in];
De Cecco, Elena
[Verfasser:in];
Bächli, Esther
[Verfasser:in];
Rudiger, Alain
[Verfasser:in];
Stüssi-Helbling, Melina
[Verfasser:in];
Huber, Lars C.
[Verfasser:in];
Zinkernagel, Annelies S.
[Verfasser:in];
Schaer, Dominik
[Verfasser:in];
Aguzzi, Adriano
[Verfasser:in];
Kochs, Georg
[Verfasser:in];
Held, Ulrike
[Verfasser:in];
Probst-Müller, Elsbeth
[Verfasser:in];
Rampini, Silvana K.
[Verfasser:in];
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
Teilen
Literatur-
verwaltung
Direktlink
Zur
Merkliste
Lösche von
Merkliste
Per Email teilen
Auf Twitter teilen
Auf Facebook teilen
Per Whatsapp teilen
- Medientyp: E-Book; Sonderdruck
- Titel: Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
- Beteiligte: Cervia, Carlo [Verfasser:in]; Nilsson, Jakob [Verfasser:in]; Zurbuchen, Yves [Verfasser:in]; Valaperti, Alan [Verfasser:in]; Schreiner, Jens [Verfasser:in]; Wolfensberger, Aline [Verfasser:in]; Raeber, Miro E. [Verfasser:in]; Adamo, Sarah [Verfasser:in]; Weigang, Sebastian [Verfasser:in]; Emmenegger, Marc [Verfasser:in]; Hasler, Sara [Verfasser:in]; Bosshard, Philipp Peter [Verfasser:in]; De Cecco, Elena [Verfasser:in]; Bächli, Esther [Verfasser:in]; Rudiger, Alain [Verfasser:in]; Stüssi-Helbling, Melina [Verfasser:in]; Huber, Lars C. [Verfasser:in]; Zinkernagel, Annelies S. [Verfasser:in]; Schaer, Dominik [Verfasser:in]; Aguzzi, Adriano [Verfasser:in]; Kochs, Georg [Verfasser:in]; Held, Ulrike [Verfasser:in]; Probst-Müller, Elsbeth [Verfasser:in]; Rampini, Silvana K. [Verfasser:in]; Boyman, Onur [Verfasser:in]
-
Erschienen:
Amsterdam [u.a.]: Elsevier BV, 2021
- Erschienen in: The journal of allergy and clinical immunology ; 127, 2 (2021), 545-557.e9
- Umfang: 1 Online-Ressource (22 Seiten); Illustrationen, Diagramme
- Sprache: Englisch
- DOI: 10.1016/j.jaci.2020.10.040
- Identifikator:
- Entstehung:
- Anmerkungen:
- Beschreibung: Abstract: Background<br>Whereas severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody tests are increasingly being used to estimate the prevalence of SARS-CoV-2 infection, the determinants of these antibody responses remain unclear.<br><br>Objectives<br>Our aim was to evaluate systemic and mucosal antibody responses toward SARS-CoV-2 in mild versus severe coronavirus disease 2019 (COVID-19) cases.<br><br>Methods<br>Using immunoassays specific for SARS-CoV-2 spike proteins, we determined SARS-CoV-2–specific IgA and IgG in sera and mucosal fluids of 2 cohorts, including SARS-CoV-2 PCR-positive patients (n = 64) and PCR-positive and PCR-negtive health care workers (n = 109).<br><br>Results<br>SARS-CoV-2–specific serum IgA titers in patients with mild COVID-19 were often transiently positive, whereas serum IgG titers remained negative or became positive 12 to 14 days after symptom onset. Conversely, patients with severe COVID-19 showed a highly significant increase of SARS-CoV-2–specific serum IgA and IgG titers after symptom onset. Very high titers of SARS-CoV-2–specific serum IgA were correlated with severe acute respiratory distress syndrome. Interestingly, some health care workers with negative SARS-CoV-2–specific serum antibody titers showed SARS-CoV-2–specific IgA in mucosal fluids with virus-neutralizing capacity in some cases. SARS-CoV-2–specific IgA titers in nasal fluids were inversely correlated with age.<br><br>Conclusions<br>Systemic antibody production against SARS-CoV-2 develops mainly in patients with severe COVID-19, with very high IgA titers seen in patients with severe acute respiratory distress syndrome, whereas mild disease may be associated with transient production of SARS-CoV-2–specific antibodies but may stimulate mucosal SARS-CoV-2–specific IgA secretion
- Zugangsstatus: Freier Zugang